BAT Reports Strong Business Growth in Next-Generation Products

Jun.08.2023
BAT Reports Strong Business Growth in Next-Generation Products
British American Tobacco reports strong growth in e-cigarettes and heated tobacco products, but warns of potential impact from business relocations from Russia and Belarus.

Recently, according to a report from news24, British American Tobacco (BAT) has released its half-year trading update and its stock price has remained stable. CEO Tadeu Marroco stated that the business revenue from electronic cigarettes and heated tobacco products has grown strongly, and once again confirmed that the company should be profitable by 2024.

 

The product portfolio of British American Tobacco (BAT) is well-balanced, featuring not only traditional cigarette brands such as Dunhill, Peter Stuyvesant, Rothmans, and Pall Mall, but also electronic and heated tobacco products, including Vuse, glo, and Velo.

 

The company still maintains a cash conversion rate of over 90% for operations, with the group expecting a mid-single digit increase in diluted earnings per share (calculated using a fixed exchange rate) and revenue growth of 3% to 5% for the full year. However, BAT has issued a warning that the projected growth may be affected due to the anticipated transfer of its Russian and Belarusian operations this year.

 

The company stated that their overall market share for cigarette sales has increased by 10 basis points in the last six months, despite disappointing performance in the American market.

 

The newly appointed CEO of BAT, Tadeu Marroco, has stated that the revenue growth of their e-cigarette and heated tobacco products is "strong" and has once again confirmed that the company should be profitable by 2024.

 

Our strategic goal is to gradually transform our product portfolio by actively encouraging adult smokers to switch to products with lower risks compared to smoking; this transformation will bring long-term value to multiple stakeholders.

 

However, BAT has also warned that its tobacco heating device brand, Glo, has seen a decline of over one percentage point in market share in key countries. Despite gaining market share in some European countries, it has faced intense competition from other products in the markets of Japan and Italy. According to market analysis, the main competitor for glo from British American Tobacco is IQOS from Philip Morris International.

 

The e-cigarette brand, Vuse, has seen a nearly three percentage point increase in market share, now holding a 39% share in the crucial e-cigarette market, and growth in the U.S. market.

 

In face of California's ban on the sale of most flavored tobacco products and e-cigarettes that took effect in December 2022, BAT has stated that the long-term impact of the flavor prohibition remains difficult to predict.

 

According to reports, mint-flavored products are continuing to be sold illegally due to lax law enforcement. We have also observed an increase in sales of flavored products in neighboring states.

 

Analysts believe that this may indicate a possibility of relaxation in the "flavor ban".

 

Currently, the disposable flavored electronic cigarette product, Vuse Go, is sold in 40 markets and is expanding sales in emerging markets such as Colombia and Peru. The initial results are "encouraging.

 

It is noteworthy that in the past year, the stock prices of BAT have dropped by 10%, which has left investors disappointed with the company's decision to suspend its new stock buyback plans.

 

Reference(s):

 

British American Tobacco maintains its profit outlook despite challenging conditions in the US cigarette market, despite suffering losses in its global operations.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Documents obtained by 2Firsts show that Sweden's Public Health Agency ordered Swedish Match to revise ingredient labels beyond the five ZYN products inspected. The dispute centers on whether flavoring ingredients must be individually disclosed, with Swedish Match citing trade-secret protection and the regulator insisting on full ingredient disclosure. The company faces a conditional penalty of SEK 2 million per month for noncompliance. As of October 22, the agency had received no appeal, despite the company's stated intention to challenge the decision.
Oct.22
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU finance ministers failed to reach agreement on tobacco excise reform at the November 9, 2026 Economic and Financial Affairs Council (ECOFIN) meeting in Brussels. The Irish Council presidency's compromise secured support from 26 of the EU's 27 member states, but Malta withheld consent, preventing the Council from reaching a general approach requiring unanimity. The reform would raise minimum taxes on conventional tobacco and bring e-cigarette liquids, heated tobacco and nicotine pouches into a common EU minimum excise framework. Finland and Estonia accepted further concessions during the meeting, while the presidency proposed separating the inclusion of nicotine pouches in the framework from setting their precise minimum tax rates. Another compromise would allow ten qualifying member states until 2036 to meet certain tobacco excise requirements. Ireland intends to continue negotiations in December.
Regulations
Nov.11
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08